Actavis Announces Proposed Senior Management Post Closing of Proposed $66 Billion Acquisition of Allergan
Actavis plc announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan, Inc., anticipated in the second quarter of 2015. Brent Saunders will continue to lead Actavis as CEO and president and a member of the board of directors. Paul Bisaro will remain executive chairman of the board of directors. Mr. Saunders will lead an expanded senior management team comprised of leaders from both Actavis and Allergan. Following the close of the deal, Douglas Ingram, current president of Allergan, will continue as a special advisor to Mr. Saunders.
Actavis announced that, following the close of the acquisition, its global brand sales and marketing will be structured into three organizations: International Brands, Branded Pharma, and Allergan Medical. Paul Navarre, Allergan corporate vice president and president Europe, Africa and the Middle East, will become executive vice president, Actavis, and president, International Brands. William Meury, Actavis executive vice president for North American Brands will become executive vice President Actavis, and president, Branded Pharma with responsibility for eye care, neurosciences, gastroenterology, urology, women’s health and other Specialty brand portfolios. Philippe Schaison, Allergan corporate vice president, president, Allergan Medical, will become executive vice president, Actavis, president, Allergan Medical, which will include facial aesthetics, medical dermatology, plastic surgery and skin-medica. These individuals will report directly to . Mr. Saunders.
With a commitment to invest more than $1 billion in brand product development, the company announced that brand pharmaceutical R&D for the combined company at close will be led by Actavis’ C. David Nicholson, PhD, senior vice president, Global Brand R&D in the role of executive vice president, Branded R&D, who will report directly to Mr. Saunders.
The combined company is expected to have more than two dozen mid- and near-term products in development, and will maintain a focus on the strategic development of innovative and durable value-enhancing brand products. The company is committed to maintaining Allergan’s research and development expertise in its therapeutic categories, which is additive to Actavis, and reiterated that it intends to maintain a strong commitment to R&D activities at Allergan’s Irvine, California location and continued investment in its development portfolio.
In its generics business, Actavis announced that Robert Stewart, currently Actavis’ chief operating officer, will become executive vice president, Actavis, and president, Generics and Global Operations. He will report directly to Mr. Saunders.
Actavis announced the senior management team for its Global Functions, which will report to Mr. Saunders. Maria Teresa (Tessa) Hilado will serve as executive vice president and chief financial officer for the combined company. Robert Bailey will serve as executive vice president, chief legal officer, and corporate secretary. Karen Ling, will serve as executive vice president and chief human resources officer; Charlie Mayr will serve as executive vice president and chief communications officer; Sigurd Kirk will serve as executive vice president corporate business development, and Jonathan Kellerman will serve as executive vice president and global chief compliance officer. These positions will report directly to Mr. Saunders.
Finally, the company announced that Alex Kelly, Actavis senior vice president and chief integration officer; and Sanjiv Patel, Allergan corporate vice president, global strategic marketing and global health outcomes strategy and research, will share jointly in the responsibility for pre-integration planning. Mr. Patel will also continue in his current role leading the Allergan Global Strategic Marketing and Global Health Outcomes Research and Strategy organization. As pre-integration planning continues, the company will focus on how to best align these groups into a larger organization to provide a vital link between the combined company’s global brand product development and commercialization activities to optimize its impact. Both Mr. Kelly and Mr. Patel will report to Mr. Saunders.